1. Home
  2. ATO vs ILMN Comparison

ATO vs ILMN Comparison

Compare ATO & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Atmos Energy Corporation

ATO

Atmos Energy Corporation

HOLD

Current Price

$169.37

Market Cap

27.2B

Sector

Utilities

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$130.62

Market Cap

18.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATO
ILMN
Founded
1906
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Oil/Gas Transmission
Medical Specialities
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.2B
18.9B
IPO Year
1987
2000

Fundamental Metrics

Financial Performance
Metric
ATO
ILMN
Price
$169.37
$130.62
Analyst Decision
Hold
Hold
Analyst Count
9
15
Target Price
$169.50
$117.27
AVG Volume (30 Days)
1.2M
1.7M
Earning Date
02-03-2026
02-05-2026
Dividend Yield
2.36%
N/A
EPS Growth
9.22
N/A
EPS
7.46
4.46
Revenue
$4,702,755,000.00
$4,288,000,000.00
Revenue This Year
$13.34
N/A
Revenue Next Year
$10.43
$2.08
P/E Ratio
$22.68
$29.04
Revenue Growth
12.91
N/A
52 Week Low
$136.05
$68.70
52 Week High
$180.65
$153.06

Technical Indicators

Market Signals
Indicator
ATO
ILMN
Relative Strength Index (RSI) 45.87 58.38
Support Level $167.43 $129.29
Resistance Level $170.78 $137.09
Average True Range (ATR) 2.85 3.78
MACD -0.04 -0.79
Stochastic Oscillator 36.06 50.64

Price Performance

Historical Comparison
ATO
ILMN

About ATO Atmos Energy Corporation

Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3.3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: